MARIANA CHAVEZ MAC GREGOR

TitleAssistant Professor
InstitutionMD Anderson
DepartmentHealth Services Research
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351. PMID: 30610588.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    2. Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. Oncologist. 2017 11; 22(11):1292-1300. PMID: 28592619.
      Citations: 15     Fields:    Translation:Humans
    3. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21. PMID: 26486734.
      Citations: 7     Fields:    Translation:Humans
    4. Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez-MacGregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153(2):417-23. PMID: 26272743.
      Citations: 4     Fields:    Translation:Humans
    5. Bambhroliya A, Chavez-MacGregor M, Brewster AM. Barriers to the Use of Breast Cancer Risk Reduction Therapies. J Natl Compr Canc Netw. 2015 Jul; 13(7):927-35. PMID: 26150584.
      Citations: 7     Fields:    Translation:Humans
    6. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol. 2015 Jul 10; 33(20):2239-45. PMID: 25987700.
      Citations: 20     Fields:    Translation:Humans
    7. Chavez-MacGregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi GN, Giordano SH. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol. 2015 Jul 01; 33(19):2176-83. PMID: 25964256.
      Citations: 24     Fields:    Translation:Humans
    8. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14. PMID: 25605252.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    9. Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez-MacGregor M. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer. 2015 Feb 17; 112(4):630-5. PMID: 25584488.
      Citations: 4     Fields:    Translation:Humans
    10. Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014 Dec; 15(13):e625-e634. PMID: 25456381.
      Citations: 58     Fields:    Translation:Humans
    11. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer. 2015 Apr; 15(2):153-60. PMID: 25454687.
      Citations: 10     Fields:    Translation:Humans
    12. Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez-MacGregor M, Yi M, Hunt KK, Strom EA. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015 Jan; 22(1):90-5. PMID: 25249256.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    13. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73. PMID: 24841348.
      Citations: 7     Fields:    Translation:Humans
    14. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 01; 88(3):553-64. PMID: 24521674.
      Citations: 53     Fields:    Translation:Humans
    15. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014 Mar; 21(3):704-16. PMID: 24515565.
      Citations: 53     Fields:    Translation:Humans
    16. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014 May 10; 32(14):1507-15. PMID: 24516019.
      Citations: 77     Fields:    Translation:Humans
    17. Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014 Mar 10; 32(8):735-44. PMID: 24470007.
      Citations: 43     Fields:    Translation:Humans
    18. Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2014 Feb; 23(2):316-23. PMID: 24296856.
      Citations: 9     Fields:    Translation:Humans
    19. Shen MC, Massarweh NN, Lari SA, Vaporciyan AA, Selber JC, Mittendorf EA, MacGregor MC, Smith BD, Kuerer HM. Clinical course of breast cancer patients with isolated sternal and full-thickness chest wall recurrences treated with and without radical surgery. Ann Surg Oncol. 2013 Dec; 20(13):4153-60. PMID: 23959054.
      Citations: 2     Fields:    Translation:Humans
    20. Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013 Nov 20; 31(33):4222-8. PMID: 24127446.
      Citations: 50     Fields:    Translation:Humans
    21. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus. 2013; 2:409. PMID: 24156086.
      Citations:    
    22. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J Cancer. 2013; 4(7):549-56. PMID: 23983819.
      Citations:    
    23. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 2013 Oct; 13(5):378-84. PMID: 23810431.
      Citations: 12     Fields:    Translation:Humans
    24. Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol. 2013 Aug 10; 31(23):e398-400. PMID: 23796991.
      Citations: 1     Fields:    Translation:Humans
    25. Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet. 2013 Jun 15; 381(9883):2077-8. PMID: 23769223.
      Citations: 1     Fields:    Translation:Humans
    26. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013 May 01; 119(9):1611-7. PMID: 23341341.
      Citations: 15     Fields:    Translation:HumansPHPublic Health
    27. Chavez-MacGregor M, Gonzalez-Angulo AM. Breast cancer in 2012: New drugs, new knowledge, new targets. Nat Rev Clin Oncol. 2013 Feb; 10(2):75-6. PMID: 23296111.
      Citations: 4     Fields:    Translation:Humans
    28. Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol. 2013 Apr; 24(4):909-16. PMID: 23139263.
      Citations: 9     Fields:    Translation:Humans
    29. Chavez-MacGregor M, Gonzalez-Angulo AM. Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs. 2012 Dec; 21(12):1835-43. PMID: 22994502.
      Citations: 7     Fields:    Translation:Humans
    30. Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol. 2012 Dec; 23(12):3063-3069. PMID: 22776706.
      Citations: 8     Fields:    Translation:Humans
    31. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15. PMID: 22736407.
      Citations: 24     Fields:    Translation:HumansCells
    32. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77. PMID: 22374333.
      Citations: 43     Fields:    Translation:HumansCells
    33. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012 Mar 15; 118(6):1498-506. PMID: 21837669.
      Citations: 6     Fields:    Translation:Humans
    34. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer. 2011 Oct; 11(5):325-31. PMID: 21764391.
      Citations: 17     Fields:    Translation:Humans
    35. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2645-52. PMID: 21632501.
      Citations: 143     Fields:    Translation:Humans
    36. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34. PMID: 21606433.
      Citations: 50     Fields:    Translation:Humans
    37. Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer. 2012 Jan 15; 118(2):326-32. PMID: 21590688.
      Citations: 5     Fields:    Translation:Humans
    38. Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YC, Giordano SH. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol. 2011 Nov; 22(11):2394-2402. PMID: 21393379.
      Citations: 3     Fields:    Translation:Humans
    39. Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer. 2011 Aug 15; 117(16):3641-9. PMID: 21656514.
      Citations: 5     Fields:    Translation:Humans
    40. Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010 Sep 01; 116(17):4168-77. PMID: 20564153.
      Citations: 10     Fields:    Translation:Humans
    41. Chávez-MacGregor M, González-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol. 2010 Jul; 12(7):461-7. PMID: 20615822.
      Citations: 5     Fields:    Translation:Humans
    42. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010 May; 11(5):421-8. PMID: 20362507.
      Citations: 95     Fields:    Translation:HumansCellsCTClinical Trials
    43. Chavez-MacGregor M, Gonzalez-Angulo AM. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group? Clin Adv Hematol Oncol. 2009 Sep; 7(9):591-8. PMID: 20020671.
      Citations: 2     Fields:    Translation:Humans
    44. Chavez-MacGregor M, van Gils CH, van der Schouw YT, Monninkhof E, van Noord PA, Peeters PH. Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. Breast Cancer Res Treat. 2008 Mar; 108(1):101-12. PMID: 18274909.
      Citations: 12     Fields:    Translation:Humans
    45. Ruvalcaba-Limón E, Robles-Vidal C, Poitevin-Chacón A, Chávez-Macgregor M, Gamboa-Vignolle C, Vilar-Compte D. Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: A case-control analysis. Breast Cancer Res Treat. 2006 Jan; 95(2):147-52. PMID: 16319989.
      Citations: 8     Fields:    Translation:Humans
    46. Chavez-Macgregor M, Aviles-Salas A, Green D, Fuentes-Alburo A, Gómez-Ruiz C, Aguayo A. Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res. 2005 Aug 01; 11(15):5396-400. PMID: 16061853.
      Citations: 7     Fields:    Translation:HumansCells
    47. Chavez-MacGregor M, Elias SG, Onland-Moret NC, van der Schouw YT, Van Gils CH, Monninkhof E, Grobbee DE, Peeters PH. Postmenopausal breast cancer risk and cumulative number of menstrual cycles. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):799-804. PMID: 15824146.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    48. Vidal-Millan S, Zeichner-Gancz I, Flores-Estrada D, Vela-Rodríguez BE, Vazquez-López MI, Robles-Vidal CD, Ramirez-Ugalde MT, Chávez-MacGregor M. A descriptive study of second primary malignancies associated to breast cancer in a mexican Hispanic population. Med Oncol. 2005; 22(1):17-22. PMID: 15750192.
      Citations: 3     Fields:    Translation:Humans
    49. Ochoa-Carrillo FJ, Chávez-Mac Gregor M, Green-Renner D, Green-Schneeweiss L. [Paraneoplastic syndromes. Associated with lung cancer]. Cir Cir. 2003 Mar-Apr; 71(2):150-61. PMID: 19764144.
      Citations:    Fields:    Translation:Humans
    50. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. Breast Diseases. 24:143-144.
    51. Estimating regimen-specific costs of chemotherapy for breast cancer. Cancer. 122:3447-3455.
    52. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. International Journal of Radiation Oncology Biology Physics. 96:637-644.
    53. Effects of multidisciplinary team working on breast cancer survival. Breast Diseases. 23:324-325.
    54. Supportive Care in Cancer. 1-12.
    55. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment.
    56. Guidelines for Guidelines. Annals of Surgical Oncology. 24.
    57. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 1-8.
    58. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 7:76362-76373.
    59. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Annals of Surgical Oncology. 1-9.
    60. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Annals of Surgical Oncology. 1-7.
    61. Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes. Journal of Clinical Oncology. 34:1072-1078.
    62. Stability of estrogen receptor status in breast carcinoma. Breast Diseases. 22:270-271.
    63. Annals of Surgical Oncology. 1-10.
    64. Practical Radiation Oncology. 6:287-295.
    65. Randomized clinical trials and observational studies. Journal of Clinical Oncology. 34:772-773.
    66. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership). Breast Diseases. 22:262-263.
    67. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Research and Treatment. 1-12.
    68. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgery.
    69. Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Supportive Care in Cancer. 1-9.
    70. High her2/centromeric probeforchromosome17fluorescence insitu hybridization ratio predicts pathologic complete response and survival outcomein patients receiving neoadjuvant systemic therapy with trastuzumab for her2-overexpressing locally advanced breast cancer. Oncologist. 21:21-27.
    71. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Journal of Clinical Oncology. 34:4040-4046.
    72. Anthracycline or trastuzumab-related cardiotoxicity. Biomarkers in Medicine. 10:315-328.
    73. The Impact of Paravertebral Block Analgesia on Breast Cancer Survival after Surgery. Regional Anesthesia and Pain Medicine. 41:696-703.
    74. Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. Academic Radiology. 24:191-199.
    75. Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer. Journal of Cancer. 6:310-318.
    76. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. British Journal of Cancer.
    77. Economic evaluation of four follow-up strategies after curative treatment for breast cancer. Breast Diseases. 23:197-198.
    78. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer.
    79. Erratum. Breast Cancer Research and Treatment. 152:417.
    CHAVEZ MAC GREGOR's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (210)
    Explore
    _
    Co-Authors (72)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _